• KOL
    • Prostate Cancer
    • Zvi Y Fuks
    • Zvi Y Fuks: Influence Statistics

      Zvi Y Fuks

      Zvi Y Fuks

      Memorial Sloan Kettering Cancer Center, New York, NY, United States | Department of Radiation Oncology, Champalimaud Centre for the Unknown, Lisbon, Portugal | Department of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Zvi Y Fuks:Expert Impact

      Concepts for whichZvi Y Fukshas direct influence:Prostate cancer,Endothelial cells,Extracellular matrix,Radiation therapy,Conformal radiotherapy,Transurethral resection,Mycosis fungoides,Platelet heparitinase.

      Zvi Y Fuks:KOL impact

      Concepts related to the work of other authors for whichfor which Zvi Y Fuks has influence:Prostate cancer,Radiation therapy,Endothelial cells,Cell death,Growth factor,Protein kinase,Brain metastases.

      KOL Resume for Zvi Y Fuks

      Year
      2022

      Memorial Sloan Kettering Cancer Center, New York, NY, United States

      Department of Radiation Oncology, Champalimaud Centre for the Unknown, Lisbon, Portugal

      2021

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, United States of America

      The Champalimaud Centre for the Unknown, Lisbon, Portugal

      Memorial Sloan Kettering Cancer Center, New York, New York

      2020

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

      The Champalimaud Centre for the Unknown, Lisbon, Portugal; Memorial Sloan Kettering Cancer Center, New York City, New York.

      Memorial Sloan Kettering Cancer Center, New York, USA

      2019

      The Champalimaud Centre for the Unknown, Lisbon, Portugal; Memorial Sloan Kettering Cancer Center, New York, New York.

      Department of Radiation Oncology.

      Champalimaud Centre, Lisbon, Portugal.

      2018

      Chamaplimaud Foundation, Lisbon, Portugal;

      2017

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

      2016

      Department of Radiation Oncology, USA

      2015

      Radiation Oncology, Champalimaud Centre for the Unknown, Lisbon, Portugal

      2014

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA

      2013

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

      2012

      Laboratory of Signal Transduction and, Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York, USA., David H. Koch Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York

      2011

      Memorial Sloan-Kettering Cancer Center, New York, NY

      2010

      Authors' Affiliations: Laboratory of Signal Transduction and Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center; Department of Pathology, Columbia University, New York, New York; and Department of Oncology and Radiation Therapy Cancer Center, University of Warmia and Mazury, Olsztyn, Poland

      From the Departments of Radiation Oncology, Urology Service, and the Departments of Surgery and Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States

      2009

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA

      Memorial Sloan Kettering Cancer Center, New York, NY

      2008

      Departments of Radiation Oncology, Pathology and Urology, Memorial Sloan-Kettering Cancer Center, New York, New York

      2007

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA

      2006

      Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

      2005

      Department of Radiation Oncology and

      Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

      2004

      Department of Radiation Oncology, Memorial Sloan-Kettering Hospital, New York, USA

      Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

      2003

      From the Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York

      2002

      Department of Radiation Oncology, New York, New York.

      2001

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NYUSA

      2000

      From the Departments of Urology, Epidemiology and Biostatistics, and Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, and the Cleveland Clinic, Cleveland, OH.

      Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA

      Memorial Sloan-Kettering Cancer Center, New York, NY U.S.A.

      Radiation Oncology, and

      1999

      From the Departments of Radiation Oncology and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.

      Department of Radiation Oncology, 1275 York Avenue, New York, NY 10021, USA

      New York, N.Y. (Presented by Dr. Zelefsky).

      1998

      Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NYUSA

      1997

      From the, Laboratory of Signal Transduction, the, Department of Radiation Oncology, the, Department of Pathology, and the, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York 10021; the, Department of Pharmacology, Inflammation Research, Amgen Inc., Boulder, Colorado 80301-2546; and the, Department of Human Genetics, Mount Sinai School of Medicine, New York 10029

      Department of Radiation Oncology and Laboratory of Signal Transduction, Memorial Sloan-Kettering Cancer CenterNew York, USA

      1996

      aDepartments of Radiation Oncology and bMedical Physics, Memorial Sloan-Kettering Cancer Center, New York, N.Y., USA

      1995

      Memorial Sloan Kettering, Cancer Center New York, NY 10021, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Zvi Y Fuks is among the top experts in the world.
      Concept World rank
      p21waf1 cip1 inhibition #1
      t1ct3 prostate cancer #1
      ceramiderich platforms apoptosis #1
      asmase plasma membranes #1
      756 presence #1
      overexpression cers2 #1
      756 factors #1
      4 years series #1
      tumor dose escalation #1
      5 reliability test #1
      activity suppressor macrophages #1
      702 648 #1
      inbred c57bl asmase #1
      patients 756 810 #1
      3dcrt gleason score #1
      4 advantage #1
      apoptosis sphingomyelin hydrolysis #1
      degradation soluble proteoglycan #1
      ceramide generation independent #1
      tpa findings #1
      interlock rate 5 #1
      thc nsaid therapy #1
      graft rejection tli #1
      combined modality protocol #1
      ceramide generation fadd #1
      2d planning dose #1
      platelet heparanase degradation #1
      advantage prone position #1
      recovery structural continuity #1
      rectal contour iso50 #1
      stimulated releases thromboxane #1
      heparanase activity exposure #1
      radiation pgi2 #1
      irradiation multiple series #1
      organ motion plans #1
      dosedistribution variables #1
      95 radiation dose #1
      pmfs outcome sdrt #1
      tli dogs graft #1
      crypt sccs #1
      conformal therapy goal #1
      inverseplanning parameters #1
      lymphography mycosis fungoides #1
      satisfactory approximations #1
      risk lung parenchyma #1
      lgr5 cescs #1
      serum transcobalamin levels #1
      improved plans average #1
      3dcrt tpi groups #1
      treatment microtron #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Zvi Y Fuks

      KOL-Index: 20326

      PURPOSE AND OBJECTIVE: Late rectal bleeding is a potentially dose limiting complication of three-dimensional conformal radiotherapy (3D-CRT) for prostate cancer. The frequency of late rectal bleeding has been shown to increase as the prescription dose rises above 70 Gy. The purpose of this study is to identify features of the cumulative dose-volume histogram (DVH) for the rectal wall that correlate with late rectal bleeding after 3D-CRT for prostate cancer.

      METHODS AND MATERIALS: ...

      Known for Rectal Bleeding | Prostate Cancer | Volume Effects | Conformal Radiotherapy | Multivariate Analysis
      KOL-Index: 19095

      PURPOSE: To compare the prostate-specific antigen (PSA) relapse-free survival outcome and incidence of late toxicity for patients with early-stage prostate cancer treated at a single institution with either three-dimensional conformal radiotherapy (3D-CRT) or transperineal permanent implantation (TPI) with iodine-125 seeds.

      MATERIALS AND METHODS: Patients with favorable-risk prostate cancer, defined as a pretreatment PSA of less than or equal to 10.0 ng/mL, Gleason score of 6 or lower, ...

      Known for Patients Tpi | Prostatic Cancer | Dimensional Conformal | Urinary Toxicity | Grade 2
      KOL-Index: 18882

      PURPOSE: We present the long-term outcome and tolerance of 3-dimensional (D) conformal and intensity modulated radiation therapy for localized prostate cancer.

      MATERIALS AND METHODS: Between October 1988 and December 1998, 1,100 patients with clinical stages T1c-T3 prostate cancer were treated with 3-D conformal or intensity modulated radiation therapy. Patients were categorized into prognostic risk groups based on pretreatment prostate specific antigen (PSA), Gleason score and clinical ...

      Known for Intensity Modulated | Dose Radiation | Conformal Radiotherapy | Localized Prostate Cancer | 5 Years Patients
      KOL-Index: 17669

      PURPOSE/OBJECTIVE: This study evaluates the dosimetric benefits and feasibility of a deep inspiration breath-hold (DIBH) technique in the treatment of lung tumors. The technique has two distinct features--deep inspiration, which reduces lung density, and breath-hold, which immobilizes lung tumors, thereby allowing for reduced margins. Both of these properties can potentially reduce the amount of normal lung tissue in the high-dose region, thus reducing morbidity and improving the ...

      Known for Lung Tumors | Dose Escalation | Deep Inspiration | Hold Technique | Dibh Plans
      KOL-Index: 16201

      PURPOSE: To determine the extent and predictors for prostatic motion in a large number of patients evaluated with multiple CT scans during radiotherapy, and evaluate the implications of these data on the design of appropriate treatment margins for patients receiving high-dose three-dimensional conformal radiotherapy.

      MATERIALS AND METHODS: Fifty patients underwent four serial computerized tomography (CT) scans, consisting of an initial planning scan and subsequent scans at the beginning, ...

      Known for Conformal Radiotherapy | Prostate Position | Seminal Vesicles | 50 Patients | Rectal Volume
      KOL-Index: 15706

      PURPOSE: Local failure is a major obstacle to the cure of locally advanced non-small-cell lung cancer. 3-Dimensional conformal radiation therapy (3-DCRT) selects optimal treatment parameters to increase dose to tumor and reduce normal tissue dose, potentially permitting dose escalation. There are several ongoing trials of dose escalation using 3-Dimensional conformal radiation therapy for non-small-cell lung cancer. We performed this analysis to determine if data derived from dose volume ...

      Known for Dose Escalation | Lung Cancer | Radiation Therapy | Dimensional Conformal | Pulmonary Toxicity
      KOL-Index: 15240

      PURPOSE: To investigate the correlations between observed clinical morbidity and dosimetric parameters for whole pelvic radiotherapy (WPRT) for prostate cancer using either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT).

      METHODS AND MATERIALS: Between December 1996 and January 2002, 27 patients with prostate adenocarcinoma were treated with conformal WPRT as part of their definitive treatment. WPRT was delivered with 3D-CRT in 14 patients and ...

      Known for Pelvic Radiotherapy | Prostate Cancer | 3dcrt Imrt | Volume Rectum | 6 Patients
      KOL-Index: 14707

      PURPOSE: The goal of tumor control probability (TCP) models is to predict local control for inhomogeneous dose distributions. All existing fits of TCP models to clinical data have utilized summaries of dose distributions (e.g., prescription dose). Ideally, model fits should be based on dose distributions in the tumor, but usually only dose-volume histograms (DVH) of the planning target volume (PTV) are available. We fit TCP models to biopsy outcome after three-dimensional conformal ...

      Known for Clinical Data | Biopsy Outcome | Prostate Cancer | Tumor Control | Probability Models
      KOL-Index: 14531

      An analysis is presented of the histopathologic, clinical, and prognostic features in a series of 405 previously untreated patients with non-Hodgkin's lymphomas referred to Stanford University Medical Center between 1960 and 1971. All biopsies were histologically classified according to the criteria of Rappaport et al. and clinical extent of disease was thoroughly evaluated prior to treatment and staged according to the Ann Arbor Classification. Nodular lymphomas constituted 44% of the ...

      Known for Nodular Lymphomas | Patients Diffuse | Clinicopathologic Correlation | 405 Cases | Criteria Rappaport
      KOL-Index: 14277

      PURPOSE: To report the acute and late toxicity and preliminary biochemical outcomes in 772 patients with clinically localized prostate cancer treated with high-dose intensity-modulated radiotherapy (IMRT).

      METHODS AND MATERIALS: Between April 1996 and January 2001, 772 patients with clinically localized prostate cancer were treated with IMRT. Treatment was planned using an inverse-planning approach, and the desired beam intensity profiles were delivered by dynamic multileaf collimation. ...

      Known for Grade 2 | Biochemical Outcome | Prostate Cancer | Dose Intensity | Late Toxicity
      KOL-Index: 14110

      PURPOSE: The purpose of this paper is to use the outcome of a dose escalation protocol for three-dimensional conformal radiation therapy (3D-CRT) of prostate cancer to study the dose-response for late rectal toxicity and to identify anatomic, dosimetric, and clinical factors that correlate with late rectal bleeding in multivariate analysis.

      METHODS AND MATERIALS: Seven hundred forty-three patients with T1c-T3 prostate cancer were treated with 3D-CRT with prescribed doses of 64.8 to 81.0 ...

      Known for Multivariate Analysis | Late Rectal | Prostate Cancer | Conformal Radiotherapy | Patients Dose
      KOL-Index: 13738

      PURPOSE: To improve the local control of patients with adenocarcinoma of the prostate we have implemented intensity modulated radiation therapy (IMRT) to deliver a prescribed dose of 81 Gy. This method is based on inverse planning and the use of dynamic multileaf collimators (DMLC). Because IMRT is a new modality, a major emphasis was on the quality assurance of each component of the process and on patient safety. In this article we describe in detail our procedures and quality assurance ...

      Known for Quality Assurance | Modulated Radiotherapy | Dmlc Imrt | Dynamic Multileaf Collimator | Dose Distribution
      KOL-Index: 13702

      PURPOSE: To prospectively assess the effect of supine vs. prone treatment position on the dose to normal tissues in prostate cancer patients treated with the three-dimensional conformal technique.

      METHODS AND MATERIALS: Twenty-six patients underwent three-dimensional treatment planning in both the supine and prone treatment positions. The planning target volume and normal tissue structures were outlined on each CAT scan slice, and treatment plans were compared to assess the effect of ...

      Known for Treatment Position | Prostate Cancer | Rectal Wall | Conformal Radiotherapy | Prescription Dose
      KOL-Index: 13335

      PURPOSE: We assessed the effect of radical prostatectomy (RP) and external beam radiotherapy (EBRT) on distant metastases (DM) rates in patients with localized prostate cancer treated with RP or EBRT at a single specialized cancer center.

      PATIENTS AND METHODS: Patients with clinical stages T1c-T3b prostate cancer were treated with intensity-modulated EBRT (> or = 81 Gy) or RP. Both cohorts included patients treated with salvage radiotherapy or androgen-deprivation therapy for biochemical ...

      Known for Patients Rp | Prostate Cancer | Metastatic Progression | External Beam Radiotherapy | Salvage Therapy

      Key People For Prostate Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Peter T Scardino
      prostate cancer active surveillance erectile function
      #3
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #4
      Johnathan I Jonathan
      prostate cancer gleason score needle biopsy
      #5
      Philip W Kantoff
      prostate cancer psma adc androgen deprivation therapy
      #6
      PATRICK CRAIG Walsh
      prostate cancer specific antigen pathological stage

      Memorial Sloan Kettering Cancer Center, New York, NY, United States | Department of Radiation Oncology, Champalimaud Centre for the Unknown, Lisbon, Portugal | Department of Radiation Oncology, and | Human Oncology and Pathogenesis Program, Memorial

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.